The Infamous, Famous Sulfonylureas and Cardiovascular Safety

Much Ado About Nothing?

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Purpose of Review: Sulfonylureas (SUs) are one of the most commonly used glucose-lowering agents worldwide. While their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings: With no dedicated cardiovascular studies to definitively answer this question, observational studies and meta-analyses abound and have reported divergent results, fueling the controversy. Studies that compared SUs to metformin or newer agents, like GLP-1 agonists and SGLT2 inhibitors, suggest a difference in cardiovascular events, yet this is likely the result of beneficial effects of the latter. Studies comparing SUs to other agents have been reassuring. Summary: SUs remain a common choice of treatment for patients with type 2 diabetes due to their exceptional value. They are effective at lowering glucose and thus contributing to the prevention of microvascular complications. Weight gain and hypoglycemia are their main side effects, although less severe when compared to insulin treatment. Their cardiovascular safety will remain a controversial topic due to lack of conclusive data, but there is no definitive evidence of harm with the second-generation agents.

Original languageEnglish (US)
Article number124
JournalCurrent Diabetes Reports
Volume17
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Safety
Glucose
Glucagon-Like Peptide 1
Metformin
Hypoglycemia
Type 2 Diabetes Mellitus
Weight Gain
Observational Studies
Meta-Analysis
Insulin
Therapeutics

Keywords

  • Cardiovascular disease
  • Cardiovascular safety
  • Healthcare cost
  • Ischemic preconditioning
  • Sulphonylurea
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The Infamous, Famous Sulfonylureas and Cardiovascular Safety : Much Ado About Nothing? / Pop, Laurentiu M.; Lingvay, Ildiko.

In: Current Diabetes Reports, Vol. 17, No. 12, 124, 01.12.2017.

Research output: Contribution to journalReview article

@article{cb5d7c2d9ed74ec4b65e1d2c625424d4,
title = "The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?",
abstract = "Purpose of Review: Sulfonylureas (SUs) are one of the most commonly used glucose-lowering agents worldwide. While their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings: With no dedicated cardiovascular studies to definitively answer this question, observational studies and meta-analyses abound and have reported divergent results, fueling the controversy. Studies that compared SUs to metformin or newer agents, like GLP-1 agonists and SGLT2 inhibitors, suggest a difference in cardiovascular events, yet this is likely the result of beneficial effects of the latter. Studies comparing SUs to other agents have been reassuring. Summary: SUs remain a common choice of treatment for patients with type 2 diabetes due to their exceptional value. They are effective at lowering glucose and thus contributing to the prevention of microvascular complications. Weight gain and hypoglycemia are their main side effects, although less severe when compared to insulin treatment. Their cardiovascular safety will remain a controversial topic due to lack of conclusive data, but there is no definitive evidence of harm with the second-generation agents.",
keywords = "Cardiovascular disease, Cardiovascular safety, Healthcare cost, Ischemic preconditioning, Sulphonylurea, Type 2 diabetes",
author = "Pop, {Laurentiu M.} and Ildiko Lingvay",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s11892-017-0954-4",
language = "English (US)",
volume = "17",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - The Infamous, Famous Sulfonylureas and Cardiovascular Safety

T2 - Much Ado About Nothing?

AU - Pop, Laurentiu M.

AU - Lingvay, Ildiko

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose of Review: Sulfonylureas (SUs) are one of the most commonly used glucose-lowering agents worldwide. While their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings: With no dedicated cardiovascular studies to definitively answer this question, observational studies and meta-analyses abound and have reported divergent results, fueling the controversy. Studies that compared SUs to metformin or newer agents, like GLP-1 agonists and SGLT2 inhibitors, suggest a difference in cardiovascular events, yet this is likely the result of beneficial effects of the latter. Studies comparing SUs to other agents have been reassuring. Summary: SUs remain a common choice of treatment for patients with type 2 diabetes due to their exceptional value. They are effective at lowering glucose and thus contributing to the prevention of microvascular complications. Weight gain and hypoglycemia are their main side effects, although less severe when compared to insulin treatment. Their cardiovascular safety will remain a controversial topic due to lack of conclusive data, but there is no definitive evidence of harm with the second-generation agents.

AB - Purpose of Review: Sulfonylureas (SUs) are one of the most commonly used glucose-lowering agents worldwide. While their efficacy is undisputed, their cardiovascular safety has been debated since the 1970’s. Recent Findings: With no dedicated cardiovascular studies to definitively answer this question, observational studies and meta-analyses abound and have reported divergent results, fueling the controversy. Studies that compared SUs to metformin or newer agents, like GLP-1 agonists and SGLT2 inhibitors, suggest a difference in cardiovascular events, yet this is likely the result of beneficial effects of the latter. Studies comparing SUs to other agents have been reassuring. Summary: SUs remain a common choice of treatment for patients with type 2 diabetes due to their exceptional value. They are effective at lowering glucose and thus contributing to the prevention of microvascular complications. Weight gain and hypoglycemia are their main side effects, although less severe when compared to insulin treatment. Their cardiovascular safety will remain a controversial topic due to lack of conclusive data, but there is no definitive evidence of harm with the second-generation agents.

KW - Cardiovascular disease

KW - Cardiovascular safety

KW - Healthcare cost

KW - Ischemic preconditioning

KW - Sulphonylurea

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85032219048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032219048&partnerID=8YFLogxK

U2 - 10.1007/s11892-017-0954-4

DO - 10.1007/s11892-017-0954-4

M3 - Review article

VL - 17

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 12

M1 - 124

ER -